X4 Pharmaceuticals Inc (XFOR) - Total Assets
Based on the latest financial reports, X4 Pharmaceuticals Inc (XFOR) holds total assets worth $253.06 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
X4 Pharmaceuticals Inc - Total Assets Trend (2015–2025)
This chart illustrates how X4 Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Also see X4 Pharmaceuticals Inc stock valuation for the company's overall valuation and market capitalisation.
X4 Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
X4 Pharmaceuticals Inc's total assets of $253.06 Million consist of 90.1% current assets and 9.9% non-current assets. Review X4 Pharmaceuticals Inc balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 74.7% |
| Accounts Receivable | $573.00K | 0.2% |
| Inventory | $4.48 Million | 1.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $9.25 Million | 3.2% |
| Goodwill | $17.35 Million | 6.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how X4 Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See XFOR stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: X4 Pharmaceuticals Inc's current assets represent 90.1% of total assets in 2025, an increase from 88.2% in 2015.
- Cash Position: Cash and equivalents constituted 74.7% of total assets in 2025, up from 71.1% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is goodwill at 6.0% of total assets.
X4 Pharmaceuticals Inc Competitors by Total Assets
Key competitors of X4 Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
X4 Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.30 | 3.19 | 6.10 |
| Quick Ratio | 11.02 | 3.05 | 6.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $199.49 Million | $50.05 Million | $67.47 Million |
X4 Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between X4 Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.24 |
| Latest Market Cap to Assets Ratio | 1.19 |
| Asset Growth Rate (YoY) | 98.3% |
| Total Assets | $290.46 Million |
| Market Capitalization | $347.01 Million USD |
Valuation Analysis
Above Book Valuation: The market values X4 Pharmaceuticals Inc's assets above their book value (1.19x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: X4 Pharmaceuticals Inc's assets grew by 98.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for X4 Pharmaceuticals Inc (2015–2025)
The table below shows the annual total assets of X4 Pharmaceuticals Inc from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $290.46 Million | +98.34% |
| 2024-12-31 | $146.45 Million | -0.55% |
| 2023-12-31 | $147.26 Million | -5.35% |
| 2022-12-31 | $155.59 Million | +32.78% |
| 2021-12-31 | $117.18 Million | -4.63% |
| 2020-12-31 | $122.87 Million | -23.54% |
| 2019-12-31 | $160.70 Million | +346.33% |
| 2018-12-31 | $36.00 Million | -55.69% |
| 2017-12-31 | $81.25 Million | +968.57% |
| 2016-12-31 | $7.60 Million | -20.04% |
| 2015-12-31 | $9.51 Million | -- |
About X4 Pharmaceuticals Inc
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections… Read more